September 18, 2024
Lung Cancer
September 13, 2024
Taletrectinib in ROS1-Positive NSCLC: Focus on Prior Tyrosine Kinase Inhibitor Exposure Status
The ASCO Post
September 13, 2024
NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC
The ASCO Post
Daily News
Stay up to date with the latest clinical headlines.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
September 11, 2024
IASLC Global Survey on Biomarker Testing Reveals Progress and Persistent Barriers in Lung Cancer Biomarker Testing
The ASCO Post
September 11, 2024
Pathway to Developing Predictive Biomarkers for Immune Checkpoint Inhibitors in NSCLC
The ASCO Post
Advertisement
Recommendations
Advertisement